Preview Mode Links will not work in preview mode

This Week in Cardiology

Jun 3, 2022

Devices for HF, Twitter for disseminating science, HDL levels, and dubious post-hoc studies are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I – Interatrial Shunts for HF

- Interatrial Shunt in HF Hints at Heart Structural, Functional Benefits

- Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

- Reducing Lung CongestIon Symptoms in Advanced Heart Failure (RELIEVE-HF)

II – Twitter for Science Communication

- Twitter Promotion Boosts Visibility, Citation for CV Research

- Twitter promotion is associated with higher citation rates of cardiovascular articles: the ESC Journals Randomized Study

- A Randomized Trial of Social Media From Circulation

III – HDL Level

- Very High HDL-C: Too Much of a Good Thing?

- Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations

- Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

IV – Dubious Sub-Studies: Omecamtiv Mecarbil

- Myosin Inhibitor May Benefit Data-Deprived Patients With Heart Failure and Low Blood Pressure

- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

- METEORIC-HF: Omecamtiv Mecarbil Does Not Improve Exercise Capacity in HFrEF Patients

- Effects of Omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial

You might also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact